It is an interesting drug they are developing, it doesn't have...

It is an interesting drug they are developing, it doesn't have the profitability of ATL1102/3 but should be a lot less risk involved. Their drug (LAT8881) aims to address Lumbar radiculopathy which impacts 3-5% of the total population. You can read more about their current test results here:

https://lateral-pharma.com/wp-content/uploads/2023/03/Lateral-Australia-Pain-Society-Conference-Poster.pdf

I also found that the drug has other uses, including limiting virus replication and severe diseases during influenza A virus infection. If they can get a steady cash flow from LAT8881, I am sure they can dedicate some money to further finding a use for ATL1102/3.